The number of young people in the U.S. with type 2 diabetes could surge by about 700% over the next four decades, with a greater burden falling on minority groups, a new model predicts. If the recent ...
The type 2 diabetes market is set to surge, rising from $28.6bn in 2016 to an estimated $64bn in 2026. The seven major markets of the US, France, Germany, Italy, Spain, UK and Japan are expected to ...
THE WOODLANDS, Texas, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from the SOTA-INS CGM Phase 3 randomized clinical trial demonstrated ...
As the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes, Lexicon’s sotagliflozin has tantalizing potential. But getting the pill to pass muster with the FDA has been problematic. The ...
Novo Nordisk continues to pioneer obesity innovation, including presentation of full Phase 3 REDEFINE 1 and 2 trial results, providing insights into the transformational potential of CagriSema ...
An interdisciplinary team of researchers from the University of Missouri, Children's Mercy Kansas City and Texas Children's Hospital has used a new data-driven approach to learn more about persons ...
A new study has shown that Mounjaro, a GLP-1-based drug, can significantly reduce blood sugar levels and support weight loss in children as young as 10 years old who are living with type 2 diabetes, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback